<DOC>
	<DOCNO>NCT01097642</DOCNO>
	<brief_summary>Ixabepilone capecitabine combination demonstrate active regimen patient metastatic breast cancer fail treatment . Cetuximab active tumor express epidermal growth factor receptor w/demonstrated activity head &amp; neck colorectal tumor may effective breast cancer know express EGFR . Study seek evaluate Ixabepilone alone combination cetuximab antitumor therapy w/randomization stratify stage ( T1N1-3M0 T2-4 N0-3M0 ) .</brief_summary>
	<brief_title>Neo-Adjuvant Study Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>Ixabepilone capecitabine combination demonstrate active regimen patient metastatic breast cancer ( MBC ) fail anthracycline taxane regimen . Cetuximab active tumor express epidermal growth factor receptor ( EGFR ) demonstrate activity head neck colorectal tumor . A proportion breast cancer know express EGFR . Cetuximab 's mechanism action suggest possibility efficacy breast cancer patient , several study show may efficacious Triple Negative Breast Cancer ( TNBC ) . This study seek evaluate Ixabepilone alone combination cetuximab possible way increase antitumor activity . In randomized open-label phase II trial , patient randomize equally 1 ) Ixabepilone 2 ) Ixabepilone plus Cetuximab . Randomization stratify disease stage ( T1N1-3M0 T2-4 N0-3M0 ) . The study 's primary objective determine pathologic complete response rate ( pCR ) ( breast axilla ) Ixabepilone versus Ixabepilone combine cetuximab patient invasive breast adenocarcinoma T1N1-N3M0 T2-4 N0-3M0 disease triple negative candidate preoperative chemotherapy . The secondary objective evaluate overall objective response rate treatment group assess safety toxicity regimen . There also tertiary , exploratory objective hopefully allow correlation biomarker expression response treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients histologic confirmation invasive breast carcinoma . Patients must intact primary tumor . Patients great equal 18 year . Patients T1N13M0 T24 N03M0 . Patients bilateral breast cancer eligible . Patients second primary breast cancer eligible . Patients Karnofsky performance scale great equal 70 % . Patients must clinically measurable disease treat neoadjuvant setting . Patients adequate bone marrow function , define peripheral granulocyte count great equal 1500/mm^3 , platelet count great equal 100000mm^3 . Patients must adequate liver function bilirubin within normal laboratory value . Alkaline phosphatase transaminase ( ALT AST ) may 1.5 x upper limit normal ( ULN ) institution . Patients adequate renal function creatinine level within normal range . Patients normal leave ventricular ejection fraction ( LVEF ) great equal 50 % . Negative serum urine pregnancy test woman childbearing potential ( WOCBP ) . WOCBP must use reliable appropriate contraceptive method study six month chemotherapy complete . WOCBP woman menopausal 12 month previous surgical sterilization . Patients must agree study biopsy . Patients must sign informed consent indicate aware investigational nature study , keep institutional policy . Patients history invasive malignancy diagnose treat within previous 5 year , except nonmelanoma skin cancer noninvasive cervical cancer . Her2Neu , ER PR positive patient exclude . Patients Inflammatory breast cancer ( IBC ) exclude . Patients organ allograft history immune compromise . Prior treatment investigational drug within precede 4 week . Chronic treatment systemic steroid another immunosuppressive agent . A Known history HIV seropositivity . Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumarin define 1 mg day ) . Other concurrent and/or uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , unstable angina , congestive heart failure New York Heart Association Class III IV , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month , chronic liver renal disease , active upper GI tract ulceration ) . Patients preexist peripheral neuropathy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>